Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: An open prospective unblinded study

Dermatology

Volumn 223, Issue 4, 2011, Pages 325-329

  Rigopoulos, D ^a   Gregoriou, S ^a,c   Makris, M ^a   Ioannides, D ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NONE   (Greece)

Author keywords

Nail psoriasis; Nail psoriasis severity index; Psoriasis; Quality of life; Ustekinumab

Indexed keywords

USTEKINUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAIL DISEASE; NAIL PSORIASIS SEVERITY INDEX; ONYCHOMYCOSIS; ONYCHOMYCOSIS SPECIFIC QUESTIONNAIRE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 84858442460     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000334482     Document Type: Article

References (18)

1. Jiaravuthisan MM, Sasseville D, Vender RB, et al: Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
2. Baran R: The burden of nail psoriasis: an introduction. Dermatology 2010; 221(suppl 1):1-5.
3. Gregoriou S, Kalogeromitros D, Kosionis N, et al: Treatment options for nail psoriasis. Exp Rev Dermatol 2008; 3: 339-344.
4. Gupta AK, Cooper EA: Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009; 13(suppl 2):S102-S106.
5. Papp KA, Carey W: Psoriasis care: new and emerging pharmacologic trends. J Cutan Med Surg 2010; 14: 119-129.
6. Rich P, Scher RK: Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212.
7. Drake LA, Patrick DL, Fleckman P, et al: The impact of onychomycosis on quality of life: development of an international onychomycosis specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41: 189-196.
8. McGonagle D, Tan AL, Benjamin M: The nail as a musculoskeletal appendage - implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97-110.
9. McGonagle D, Palmou Fontana N, Tan AL, Benjamin M: Nailing down the genetic and immunological basis for psoriatic disease. Dermatology 2010; 221(suppl 1):15-22.
10. Rich P, Langley R, Guzzo C, et al: Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial (poster FP107).17th Congr EADV, Paris, September 2008.
11. Leonardi CL, Kimball AB, Papp KA, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
12. Augustin M, Reich K, Blome C, et al: Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-585.
13. Augustin M, Ogilvie A: Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221(suppl 1):23-28.
14. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009; 13(suppl 2):S102-106.
15. Rigopoulos D, Gregoriou S, Stratigos A, et al: Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453-456.
16. Rigopoulos D, Gregoriou S, Lazaridou E, et al: Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-534.
17. Langley RG, Daudén E: Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010; 221(suppl 1):29-42.
18. Reich K, Ortonne J-P, Kerkmann U, Wang Y, Saurat J-H, Papp K, Langley R, Griffiths CEM: Skin and nail responses after 1 year of infliximab therapy in patients with moderate- to-severe psoriasis: a retrospective analysis of the EXPRESS trial. Dermatology 2010; 221: 172-178.